ASX - By Stock
|
IMM |
Re:
What have we got?
|
|
Bylosellhi
|
26 |
11K |
1 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
26
|
11K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
6 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
2.7K
|
1.1M
|
6
|
|
ASX - By Stock
|
IMM |
Re:
EFTI at 90
|
|
Bylosellhi
|
42 |
16K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
42
|
16K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
EFTI at 90
|
|
Bylosellhi
|
42 |
16K |
6 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
42
|
16K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
TACTI-003 likelihood of success based on data comparison
|
|
Bylosellhi
|
2 |
1.3K |
4 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
2
|
1.3K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: CHDR to conduct first-in-human phase 1 trial of IMP761
|
|
Bylosellhi
|
10 |
4.2K |
10 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
10
|
4.2K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Ceasing to be a substantial holder
|
|
Bylosellhi
|
11 |
5.0K |
2 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
11
|
5.0K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
4 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
743
|
332K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
743
|
332K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
4 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
743
|
332K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
21 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
743
|
332K
|
21
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
10 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
743
|
332K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: First Clinical Data announced from 90mg Dosing of Efti
|
|
Bylosellhi
|
56 |
30K |
1 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
56
|
30K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: First Clinical Data announced from 90mg Dosing of Efti
|
|
Bylosellhi
|
56 |
30K |
4 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
56
|
30K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
13 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
2.7K
|
1.1M
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
1 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
2.7K
|
1.1M
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: First Clinical Data announced from 90mg Dosing of Efti
|
|
Bylosellhi
|
56 |
30K |
22 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
56
|
30K
|
22
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
11 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
2.7K
|
1.1M
|
11
|
|
ASX - By Stock
|
IMM |
Re:
An obsevation re Eftiligomab alfa
|
|
Bylosellhi
|
24 |
8.5K |
4 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
24
|
8.5K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
1 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
743
|
332K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
4 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
743
|
332K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Is 2024 Efti's year?....
|
|
Bylosellhi
|
13 |
7.4K |
9 |
01/01/24 |
01/01/24 |
ASX - By Stock
|
13
|
7.4K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
The reason for the price increase ???
|
|
Bylosellhi
|
19 |
11K |
2 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
19
|
11K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Only a matter of time
|
|
Bylosellhi
|
19 |
10K |
1 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
19
|
10K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
|
|
Bylosellhi
|
17 |
9.3K |
7 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
17
|
9.3K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
|
|
Bylosellhi
|
17 |
9.3K |
19 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
17
|
9.3K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
3 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to Participate in November Investor Events
|
|
Bylosellhi
|
2 |
1.4K |
17 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
2
|
1.4K
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep reports promising data from INSIGHT-003 trial
|
|
Bylosellhi
|
10 |
5.3K |
13 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
10
|
5.3K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep receives Australian R&D Tax Incentive
|
|
Bylosellhi
|
2 |
1.0K |
0 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
2
|
1.0K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
19 |
21/10/23 |
21/10/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
5 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
9 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
0 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Commercial Scale Manufacturing of Efti for Clinical Trials
|
|
Bylosellhi
|
29 |
12K |
1 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
29
|
12K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
2 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
743
|
332K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Investor Update
|
|
Bylosellhi
|
7 |
3.9K |
1 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
7
|
3.9K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
2 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
0 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
743
|
332K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
10 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
10
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Final Positive Data In 2nd Line Head And Neck Squamous Cell Carcinoma
|
|
Bylosellhi
|
8 |
3.8K |
0 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
8
|
3.8K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Final Positive Data In 2nd Line Head And Neck Squamous Cell Carcinoma
|
|
Bylosellhi
|
8 |
3.8K |
10 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
8
|
3.8K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Trading Halt
|
|
Bylosellhi
|
37 |
12K |
0 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
37
|
12K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
0 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
743
|
332K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC
|
|
Bylosellhi
|
27 |
15K |
6 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
27
|
15K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Bylosellhi
|
743 |
332K |
3 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
743
|
332K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Quarterly Activities Report and Appendix 4C
|
|
Bylosellhi
|
7 |
4.1K |
7 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
7
|
4.1K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Quarterly Activities Report and Appendix 4C
|
|
Bylosellhi
|
7 |
4.1K |
15 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
7
|
4.1K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
|
|
Bylosellhi
|
9 |
3.9K |
8 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
9
|
3.9K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Bylosellhi
|
2.7K |
1.1M |
6 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
6
|
|